You are here: Industry Insights > cipla

News List

Cipla settles patent litigation of Revlimid (lenalidomide) capsules with Celgene expresspharma
December 14, 2020
Celgene has agreed to provide Cipla with a license to Celgene’s patents required to manufacture and sell certain volume-limited amounts of generic lenalidomide in the US beginning on a confidential date that is some time after March 2022.
Cipla signs licensing pact with MultiG for COVID-19 rapid antibody test kit expresspharma
November 19, 2020
'Covi-G' has been commercialised in 20+ countries, with sensitivity and specificity exceeding 92 per cent, informs company.
Cipla launches ELIFast for COVID-19 antibody detection expresspharma
October 29, 2020
Cipla announced the commercialisation of antibody detection kits for COVID-19 in India. It is in partnership with KARWA under the technology transfer from the Indian Council of Medical Research (ICMR).
Cipla launches Nintib (Nintedanib) to treat Idiopathic Pulmonary Fibrosis expresspharma
October 22, 2020
Cipla has launched generic Nintedanib for the treatment of Idiopathic Pulmonary Fibrosis (IPF). Available as 100 mg and 150 mg capsules, it will be marketed under the brand name Nintib.
Cipla gets US FDA approval for dimethyl fumarate DR capsules expresspharma
September 27, 2020
It is indicated for the treatment of relapsing forms of multiple sclerosis.
Stempeutics’ allogeneic cell therapy gets DCGI approval, Cipla to market and distribute Stempeucel expresspharma
August 21, 2020
Indicated for the treatment of CLI due to Buerger’s Disease and Atherosclerotic Peripheral Arterial Disease, it is the first allogeneic cell therapy product to be approved for commercial use in India.
Remdesivir shortage is India is easing: Cipla expresspharma
August 13, 2020
The company has informed that it has started producing remdesivir at a plant in Goa in western India to ramp up production.
CSIR-IICT develops cost effective process technology for Favipiravir expresspharma
July 27, 2020
The research lab announced that its had transferred the technology to Cipla, which has recently DCGI for permission to launch the COVID-19 treatment in India.
Cipla, Amgen settle case involving generic cinacalcet hydrochloride tablets expresspharma
July 21, 2020
Cipla's cinacalcet hydrochloride tablets, in the strengths of 30mg, 60mg and 90mg, are generic versions of Sensipar, a branded drug marketed by Amgen Inc.
Cipla receives final approval for generic version of Shire’s Firazyr expresspharma
July 15, 2020
Icatibant injection is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older.

Previous page 1 2 3 4 5 6 7 8 Next page